UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used to get the London-based startup fully operational.
Investors of the seed funding round include Lionheart Ventures, Convergence Partners and Exceptional Ventures. The latter was co-founded by Paolo Pio, former MD of Europe at Joyance Partners and Matt Cooper, who also co-founded Capital One Bank, Tandem Bank and was chairman of Octopus Capital Group.
